Time-homogeneous Markov process for HIV/AIDS progression under a combination treatment therapy: cohort study, South Africa

Table 6 Hazard ratios for the covariates on intensities

(i, j)	VLBL	DTB	TBB4	Gender	React	CD4BL	WSBL	Age
(1, 2)	0.69	2.29	0.31	2.04	4.72	1.17	0.55	1.45
(1, 6)	1.57	0.87	1.11	1.55	0.60	1.30	1.11	0.83
(1, 7)	1.01	0.96	1.00	1.26	0.68	0.92	0.56	0.40
(2, 1)	0.48	1.14	0.76	1.33	1.46	1.17	0.74	2.63
(2, 3)	0.92	1.98	0.67	6.46	0.67	1.37	0.26	0.40
(2, 6)	1.12	0.96	1.69	1.45	0.54	0.997	1.16	1.10
(2, 7)	1.30	1.19	1.92	0.93	0.73	1.33	0.79	0.70
(3, 2)	0.68	1.58	1.10	2.35	2.08	0.69	0.75	0.83
(3, 4)	0.42	2.55	0.53	1.04	0.55	1.57	1.06	0.89
(3, 6)	0.92	1.17	2.03	1.20	0.59	1.05	1.32	1.77
(3, 7)	1.34	0.86	2.34	0.72	0.20	1.20	0.54	2.06
(4, 3)	1.52	1.72	0.86	0.61	1.02	0.27	0.84	1.08
(4, 5)	0.74	2.25	1.65	1.36	0.65	1.05	0.46	0.89
(4, 6)	1.31	1.09	1.09	1.59	0.22	1.01	1.40	1.96
(4, 7)	1.56	1.17	1.88	0.58	0.36	1.02	0.52	2.18
(5, 4)	0.51	1.86	1.02	0.81	1.32	0.61	0.40	0.63
(5, 6)	0.92	0.65	0.41	2.10	0.06	1.003	2.09	2.60
(5, 7)	0.97	1.20	0.88	1.19	0.66	0.87	0.40	2.31

ISSN: 1742-4682